°ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Coronary Stents Market Size, Share & Trends Analysis Report By Product (Bare Metal Stents (BMS), Drug Eluting Stents (DES), Bioresorbable Vascular Scaffold), By End Use (Inpatient and Outpatient Facilities), By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1631481
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,443,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,862,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,700,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

°ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 97¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀº 2025-2030³â±îÁö ¿¬Æò±Õ 2.6%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÃÖ¼Òħ½À ¼ö¼ú ¹× °æÇÇÀû °ü»óµ¿¸Æ ÁßÀç¼ú(PCI) ½Ã¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÇâÈÄ ¸î ³â µ¿¾È ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ï´Ù. ¿¹¸¦ µé¾î, The Korean Journal of Thoracic and Cardiovascular Surgery¿¡ µû¸£¸é, 2016³â °ü»óµ¿¸ÆÁúȯ(CAD)¿¡ ´ëÇÑ PCI ºñÀ²Àº 78%, ±¹°¡º° PCI ºñÀ²Àº 96%·Î ¼¼°è Æò±ÕÀ» Å©°Ô »óȸÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ¿¡ µû¶ó CAD À¯º´·üÀÇ Àü·Ê ¾ø´Â Áõ°¡¿Í ÇÔ²² À̵é CAD ȯÀÚ¿¡°Ô ½ÃÇàµÇ´Â PCIÀÇ ºñÀ²ÀÌ Áõ°¡ÇÏ¿© È¿°úÀûÀÎ °ü»óµ¿¸Æ ½ºÅÙÆ® ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±â¼úÀÇ ¹ßÀü°ú 2¼¼´ë ¾à¹° ¿ëÃâ ½ºÅÙÆ®ÀÇ Ãâ½Ã´Â ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Abbott Laboratories LaboratoriesÀÇ XIENCE Sierra´Â 2018³â 5¿ù ¹Ì±¹¿¡¼­ CTO ÀûÀÀÁõÀ¸·Î ½ÂÀÎµÈ ÃÖÃÊÀÇ DES°¡ µÇ¾úÀ¸¸ç, 2019³â ÃÊ MedtronicÀº CTO ÀûÀÀÁõ¿¡ ´ëÇÑ ÀÚ»çÀÇ Resolute ½Ã¸®Áî DESÀÇ CTO ÀûÀÀÁõ¿¡ ´ëÇÑ FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ¶ÇÇÑ, ¸¹Àº ±â¾÷µéÀÌ ÃÖ±Ù ¹Ì±¹¿¡¼­ »õ·Î¿î ¹öÀüÀÇ °ü»óµ¿¸Æ ½ºÅÙÆ® ½Ã½ºÅÛÀ» Ãâ½ÃÇϰí ÀÖÀ¸¸ç, ƯÈ÷ Boston ScientificÀÇ Synergy MegatronÀº 2021³â 1¿ù¿¡, Abbott LaboratoriesÀÇ XIENCE Skypoint´Â 2021³â 6¿ù¿¡ Ãâ½ÃµÇ¾ú½À´Ï´Ù.

COVID-19ÀÇ ¼¼°èÀû ´ëÀ¯ÇàÀº °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. Àü ¼¼°è ÀÇ»çÇùȸÀÇ Áöħ¿¡ µû¸£¸é, ½Ã¼ú ¿¬±â´Â ÁÖ·Î Àû°Ý ȯÀÚ¿¡°Ô ´ú ±ä±ÞÇÑ ½Ã¼ú°ú ¼±ÅÃÀû ½Ã¼ú¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹½ÉÀåÇÐȸ(ACC)ÀÇ 2020³â Áöħ¿¡ µû¸£¸é, COVID-19 À¯ÇàÀÌ ÀýÁ¤¿¡ ´ÞÇßÀ» ¶§ CTO ÁßÀç½Ã¼úÀ̳ª °¨½Ã Ç÷°üÁ¶¿µ¼ú°ú °°ÀÌ ±ä±ÞÇÏÁö ¾ÊÀº ½Ã¼úÀ» ¿¬±âÇÒ °ÍÀ» ±Ç°íÇß½À´Ï´Ù. ÀÌ·¯ÇÑ °¡À̵å¶óÀÎÀº Àü ¼¼°è ÀÇ»çµéÀÇ Ä¡·á °áÁ¤¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯·´½ÉÀåÇÐȸÀÇ ±Ç°í¿¡ µû¸£¸é, ¸ðµç ±ä±Þ ¹× ÀÀ±Þ PCI ½Ã¼ú(STEMI, °íÀ§Çè ¶Ç´Â ÁßÀ§Çè NSTEMI, ½ÉÀμº ¼îÅ©, ºÒ¾ÈÁ¤ Çù½ÉÁõ Ä¡·á)Àº COVID-19ÀÇ À¯ÇàÀÌ ÃÖ°íÁ¶¿¡ ´ÞÇßÀ» ¶§¿Í ÀÌÈÄ COVID-19 ÀçÀ¯Çà ½Ã¿¡µµ °è¼Ó ½ÃÇàµÇ¾î¾ß Çϸç, ¼±ÅÃÀû PCI ½Ã¼ú(CTO ÁßÀç½Ã¼ú ¶Ç´Â NYHA II Áõ»ó Ä¡·á)¸¸ ¿¬±âÇØ¾ß ÇÕ´Ï´Ù.

¶ÇÇÑ, COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀåÀÇ È¸º¹Àº ÀÀ±Þ PCI ½Ã¼úÀÇ Áö¼ÓÀûÀÎ ½ÃÇà°ú ºñ¼±ÅÃÀû ½Ã¼úÀÇ °¡µ¿·ü Áõ°¡·Î ÀÎÇØ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀåÀº °øÀû ¸ÞµðÄÉ¾î ¹× ¸ÞµðÄÉÀÌµå ¼­ºñ½º ¼¾ÅÍ(CMS)¿Í ¹Î°£ ÁöºÒ ±â°üÀÌ Á¦°øÇÏ´Â º¸Çè¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °æµ¿¸Æ ½ºÅÙÆ® ½Ã¼ú¿¡ ´ëÇÑ º¸Çè Àû¿ëÀº Á¦Ç° ¹× ¼­ºñ½º Á¦°ø¾÷ü¸¦ Æ÷ÇÔÇÑ Àü±¹ÀûÀÎ º¸Çè Àû¿ë °áÁ¤¿¡ µû¶ó °áÁ¤µÇ¸ç, 2020³â 1¿ùºÎÅÍ CMS´Â ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ(ASC)¿¡¼­ ½ÃÇàµÇ´Â ÀϺΠÇ÷°ü¼ºÇü¼ú ¹× ½ºÅÙÆ® ½Ã¼ú¿¡ ´ëÇÑ »óȯÀ» Á¦¾ÈÇÏ¿© ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼öÀÍÀ» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå : Á¦Ç°º°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå °ü»óµ¿¸Æ ½ºÅÙÆ® ½ÃÀå : Á¦Ç°°ú ÃÖÁ¾ ¿ëµµ¿¡ ÀÇÇÑ Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Coronary Stents Market Growth & Trends:

The global coronary stents market size is expected to reach USD 9.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 2.6% from 2025 to 2030. Increasing adoption of minimally invasive surgeries and Percutaneous Coronary Intervention (PCI) procedures is expected to drive the market in the coming years. For instance, according to The Korean Journal of Thoracic and Cardiovascular Surgery, the proportion of PCI for Coronary Artery Disease (CAD) was 78% in 2016, and the country-specific PCI proportion was 96%, which was significantly higher than the global average. As a result, the unprecedented growth in CAD incidence, along with an increase in the proportion of PCIs done in these CAD patients, is expected to raise demand for an effective coronary stent technology.

Technological advancement and the launch of 2nd generation drug-eluting stents are further fueling the growth. For instance, Abbott Laboratories Laboratories' XIENCE Sierra became the first DES approved for CTO indications in the US in May 2018. Medtronic followed suit in early 2019, obtaining FDA approval for the use of its Resolute range of DES in CTO indications. In addition, many companies have recently launched newer versions of their coronary stent systems in the US, notably Boston Scientific's Synergy Megatron in January 2021 and Abbott Laboratories Laboratories' XIENCE Skypoint in June 2021.

The global COVID-19 pandemic has had a negative impact on the market for coronary stents. According to guidelines from physician societies throughout the world, procedure deferrals primarily impacted less urgent or elective procedures for eligible patients. ACC's ((American College of Cardiology) 2020 guidance, for instance, recommended postponing non-urgent procedures like CTO interventions and surveillance angiography during the peak of the COVID-19 pandemic. These guidelines have influenced physicians' treatment decisions throughout the world. Additionally, according to the European Society of Cardiology recommendations, all emergency and urgent PCI procedures (treatment of STEMI, high or intermediate risk NSTEMI, cardiogenic shock, and unstable angina) should be continued during the peak of the pandemic and in the subsequent resurgence of COVID-19, while only elective PCI procedures (CTO interventions or treatment of NYHA II symptoms) should be deferred.

Moreover, recovery of the coronary stent market from the COVID-19 pandemic is anticipated to be aided by the continuous performance of urgent PCI procedures and an increase in capacity utilization for performing non-elective procedures.

The coronary stent market is driven by reimbursement coverage provided by the general public Center for Medicare & Medicaid Services (CMS) and private payers. The coverage is availed under national coverage determination for carotid artery stenting, including products and service providers. From January 2020, the Centers for Medicare & Medicaid Services (CMS) proposed reimbursement for some angioplasty and stenting procedures performed in the ambulatory surgical centers (ASC), which is expected to boost the market revenue over the forecast period.

Coronary Stents Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Coronary Stents Market Variables, Trends & Scope

Chapter 4. Coronary Stents Market: Product Estimates & Trend Analysis

Chapter 5. Coronary Stents Market: End Use Estimates & Trend Analysis

Chapter 6. Coronary Stents Market: Regional Estimates & Trend Analysis by Product and End Use

Chapter 7. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â